13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001816307
Total reported value
$962.2M
$962.2M
61 檔
13.5%
The Q4 2024 SEC filing reveals that Silverarc Capital Management, LLC held a total portfolio value of $962.2M, covering 61 public equity positions.
During Q4 2024, Silverarc Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | Stock-Other | 6.85% | -3.71% | EXIT | |
| 2 | ✓ | Merus N V | Stock-Other | 6.26% | — | +7.15% | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 5.62% | -0.22% | +7.06% | |
| 4 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 5.24% | — | +47.91% | |
| 5 | AKRO | Akero Therapeutics Inc | Stock-Other | 4.50% | — | +15.59% | |
| 6 | VCYT | Veracyte Inc | Stock-Other | 4.36% | +1.35% | +6.95% | |
| 7 | ERAS | Erasca Inc | Stock-Other | 4.14% | -0.66% | +8.60% | |
| 8 | PLRX | Pliant Therapeutics Inc | Stock-Other | 3.79% | — | — | |
| 9 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.56% | +0.64% | +224.86% | |
| 10 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.46% | — | +14.32% | |
| 11 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.35% | +0.87% | +7.17% | |
| 12 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 3.27% | — | +7.17% | |
| 13 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.61% | +2.22% | +24.34% | |
| 14 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.19% | -1.89% | EXIT | |
| 15 | KOD | Kodiak Sciences Inc | Stock-Other | 2.18% | -1.65% | +100.00% | |
| 16 | PSTXUSD | Poseida Therapeutics Inc | Stock-Other | 2.13% | — | -72.55% | |
| 17 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.08% | -0.59% | +7.17% | |
| 18 | TELA | Tela Bio Inc | Stock-Other | 2.03% | +0.03% | +172.52% | |
| 19 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.73% | -1.70% | EXIT | |
| 20 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.65% | — | -2.97% | |
| 21 | COGT | Cogent Biosciences Inc | Stock-Other | 1.57% | -0.01% | -24.58% | |
| 22 | ASND | Ascendis Pharma A/S | Stock-Other | 1.55% | -2.91% | EXIT | |
| 23 | IRON | Disc Medicine Inc | Stock-Other | 1.53% | -0.65% | +6.28% | |
| 24 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.46% | -0.58% | EXIT | |
| 25 | ELUT | Elutia Inc | Stock-Other | 1.46% | -0.05% | +8.29% | |
| 26 | ✓ | Biodesix Inc | Stock-Other | 1.45% | — | +21.66% | |
| 27 | ✓ | Akero Therapeutics Inc | Stock-Other | 1.34% | — | — | |
| 28 | GOSS | Gossamer Bio Inc | Stock-Other | 1.22% | — | +9.33% | |
| 29 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.22% | -0.06% | +8.16% | |
| 30 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.18% | — | — | |
| 31 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.14% | — | — | |
| 32 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.13% | -5.91% | EXIT | |
| 33 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.06% | — | — | |
| 34 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.96% | +0.96% | -5.91% | |
| 35 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.90% | — | +116.11% | |
| 36 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.80% | — | +64.89% | |
| 37 | INCY | Incyte CORP | Stock-Healthcare | 0.74% | — | — | |
| 38 | PCVX | Vaxcyte Inc | Stock-Other | 0.73% | +0.02% | -32.58% | |
| 39 | GERN | Geron CORP | Stock-Other | 0.71% | — | -48.93% | |
| 40 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.66% | +0.69% | +52.15% | |
| 41 | ✓ | Compugen LTD | Stock-Other | 0.54% | -0.01% | +8.21% | |
| 42 | CERS | Cerus CORP | Stock-Other | 0.53% | +0.46% | +6.15% | |
| 43 | ✓ | Syndax Pharmaceuticals Inc | Stock-Other | 0.50% | +0.82% | — | |
| 44 | ABVX | Abivax Sa-adr | Stock-Other | 0.46% | -1.09% | -38.24% | |
| 45 | ✓ | Stock-Other | 0.43% | — | -37.83% | ||
| 46 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.42% | — | — | |
| 47 | DCTH | Delcath Systems Inc | Stock-Other | 0.41% | — | — | |
| 48 | QURE | uniQure N.V. | Stock-Other | 0.39% | +0.50% | NEW | |
| 49 | ✓ | Modular Med Inc | Stock-Other | 0.38% | — | -11.67% | |
| 50 | KALAEUR | Kala Bio Inc | Stock-Other | 0.35% | — | — |
According to official SEC Form 13F filings, Silverarc Capital Management, LLC reported a total U.S. public equity portfolio value of $962.2M across 61 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NUVL, MERUS N V, INSM) accounted for 13.5% of total reported equity market value during Q4 2024.
During Q4 2024, Silverarc Capital Management, LLC's top holdings by market value included NUVL (6.8%)、MERUS N V (6.3%)、INSM (5.6%). The largest single position, NUVL, represented 6.8% of total portfolio value.
In Q4 2024, Silverarc Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.